Mutations and Effects on Rifampin Resistance in

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2021 Oct 22

PMID 34675557

Citations 27

Authors

Ma-Chao Li

Jie Lu

Yao Lu

Tong-Yang Xiao

Hai-Can Liu

Shi-Qiang Lin

Da Xu

Gui-Lian Li

Xiu-Qin Zhao

Zhi-Guang Liu

Li-Li Zhao

Kang-Lin Wan

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the mutations within the whole gene of and analyze their effects on rifampin (RIF) resistance based on crystal structure.

Methods: We sequenced the entire gene in 175 tuberculosis isolates and quantified their minimum inhibitory concentrations using microplate-based assays. Additionally, the structural interactions between wild-type/mutant RpoB and RIF were also analyzed.

Results: Results revealed that a total of 34 mutations distributed across 17 different sites within the whole gene were identified. Of the 34 mutations, 25 could alter the structural interaction between RpoB and RIF and contribute to RIF resistance. Statistical analysis showed that S450L, H445D, H445Y and H445R mutations were associated with high-level RIF resistance, while D435V was associated with moderate-level RIF resistance.

Conclusion: Some mutations within the gene could affect the interaction between RpoB and RIF and thus are associated with RIF resistance. These findings could be helpful to design new antibiotics and develop novel diagnostic tools for drug resistance in TB.

Citing Articles

Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis.

Vadakunnel M, Nehru V, Brammacharry U, Ramachandra V, Palavesam S, Muthukumar A BMC Infect Dis. 2025; 25(1):284.

PMID: 40016696 PMC: 11866845. DOI: 10.1186/s12879-025-10655-6.

Integrative genomics would strengthen AMR understanding through ONE health approach.

Liu C, Pandey R Heliyon. 2025; 10(14):e34719.

PMID: 39816336 PMC: 11734142. DOI: 10.1016/j.heliyon.2024.e34719.

Efficacy of Xpert MTB/RIF assay in detecting Mycobacterium tuberculosis in samples with different results by smear and culture in a coastal city with high incidence of tuberculosis.

Feng G, Jiang H, Chen Y BMC Infect Dis. 2025; 25(1):55.

PMID: 39799307 PMC: 11725220. DOI: 10.1186/s12879-025-10446-z.

Large-scale proteogenomics characterization of microproteins in Mycobacterium tuberculosis.

de Souza E, Dalberto P, Miranda A, Saghatelian A, Pinto A, Basso L Sci Rep. 2024; 14(1):31186.

PMID: 39732784 PMC: 11682046. DOI: 10.1038/s41598-024-82465-w.

Comprehensive profile of the companion animal gut microbiome integrating reference-based and reference-free methods.

Branck T, Hu Z, Nickols W, Walsh A, Bhosle A, Short M ISME J. 2024; 18(1).

PMID: 39394961 PMC: 11523182. DOI: 10.1093/ismejo/wrae201.

References

Sun Q, Xiao T, Liu H, Zhao X, Liu Z, Li Y . Mutations within Are Associated with Variable Level of Ethambutol Resistance in Mycobacterium tuberculosis Isolates from China. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740351. DOI: 10.1128/AAC.01279-17. View

Rothman-Denes L . Structure of Escherichia coli RNA polymerase holoenzyme at last. Proc Natl Acad Sci U S A. 2013; 110(49):19662-3. PMC: 3856807. DOI: 10.1073/pnas.1320604110. View

Ning Q, Wang D, Cheng F, Zhong Y, Ding Q, You J . Predicting rifampicin resistance mutations in bacterial RNA polymerase subunit beta based on majority consensus. BMC Bioinformatics. 2021; 22(1):210. PMC: 8063314. DOI: 10.1186/s12859-021-04137-0. View

Xu G, Liu H, Jia X, Wang X, Xu P . Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: The phenomenon of drug resistance is complex. Tuberculosis (Edinb). 2021; 128:102083. DOI: 10.1016/j.tube.2021.102083. View

Mohajeri P, Sadri H, Farahani A, Norozi B, Atashi S . Frequency of Mutations Associated with Rifampicin Resistance in Mycobacterium tuberculosis Strains Isolated from Patients in West of Iran. Microb Drug Resist. 2014; 21(3):315-9. DOI: 10.1089/mdr.2014.0075. View

Sharma D, Bisht D, Khan A . Potential Alternative Strategy against Drug Resistant Tuberculosis: A Proteomics Prospect. Proteomes. 2018; 6(2). PMC: 6027512. DOI: 10.3390/proteomes6020026. View

Jamieson F, Guthrie J, Neemuchwala A, Lastovetska O, Melano R, Mehaffy C . Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014; 52(6):2157-62. PMC: 4042728. DOI: 10.1128/JCM.00691-14. View

Wi Y, Greenwood-Quaintance K, Brinkman C, Lee J, Howden B, Patel R . Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations. Int J Antimicrob Agents. 2017; 51(5):670-677. DOI: 10.1016/j.ijantimicag.2017.12.019. View

Friedrich S, Venter A, Kayigire X, Dawson R, Donald P, Diacon A . Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol. 2011; 49(8):2827-31. PMC: 3147741. DOI: 10.1128/JCM.00138-11. View

10.

Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M . Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2011; 44(1):106-10. PMC: 3246538. DOI: 10.1038/ng.1038. View

11.

Williams D, Spring L, Collins L, MILLER L, Heifets L, GANGADHARAM P . Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998; 42(7):1853-7. PMC: 105697. DOI: 10.1128/AAC.42.7.1853. View

12.

Campbell E, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A . Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001; 104(6):901-12. DOI: 10.1016/s0092-8674(01)00286-0. View

13.

Berrada Z, Lin S, Rodwell T, Nguyen D, Schecter G, Pham L . Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis. 2016; 85(2):177-81. PMC: 4873381. DOI: 10.1016/j.diagmicrobio.2016.01.019. View

14.

Ramaswamy S, Musser J . Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 2000; 79(1):3-29. DOI: 10.1054/tuld.1998.0002. View

15.

Shea J, Halse T, Kohlerschmidt D, Lapierre P, Modestil H, Kearns C . Low-Level Rifampin Resistance and Mutations in Mycobacterium tuberculosis: an Analysis of Whole-Genome Sequencing and Drug Susceptibility Test Data in New York. J Clin Microbiol. 2020; 59(4). PMC: 8579749. DOI: 10.1128/JCM.01885-20. View

16.

Louw G, Warren R, Gey van Pittius N, McEvoy C, Van Helden P, Victor T . A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother. 2009; 53(8):3181-9. PMC: 2715638. DOI: 10.1128/AAC.01577-08. View

17.

Swain S, Sharma D, Hussain T, Pati S . Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in . Emerg Microbes Infect. 2020; 9(1):1651-1663. PMC: 7473167. DOI: 10.1080/22221751.2020.1785334. View

18.

Rigouts L, Gumusboga M, De Rijk W, Nduwamahoro E, Uwizeye C, de Jong B . Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol. 2013; 51(8):2641-5. PMC: 3719602. DOI: 10.1128/JCM.02741-12. View

19.

Lin W, Mandal S, Degen D, Liu Y, Ebright Y, Li S . Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition. Mol Cell. 2017; 66(2):169-179.e8. PMC: 5438085. DOI: 10.1016/j.molcel.2017.03.001. View

20.

Molodtsov V, Scharf N, Stefan M, Garcia G, Murakami K . Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis. Mol Microbiol. 2016; 103(6):1034-1045. PMC: 5344776. DOI: 10.1111/mmi.13606. View